{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137043772859136.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/jbmr.4049"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjbmr.4049"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.4049"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jbmr.4049"}},{"identifier":{"@type":"URI","@value":"https://academic.oup.com/jbmr/article-pdf/35/6/1009/55453761/jbmr4049.pdf"}}],"dc:title":[{"@value":"Osteoporosis Management in the Era of COVID-19"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>ABSTRACT</jats:title>\n               <jats:p>Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available. © 2020 American Society for Bone and Mineral Research.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137043772859268","@type":"Researcher","foaf:name":[{"@value":"Elaine W Yu"}],"jpcoar:affiliationName":[{"@value":"Endocrine Unit Massachusetts General Hospital/Harvard Medical School Boston MA USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043772859265","@type":"Researcher","foaf:name":[{"@value":"Elena Tsourdi"}],"jpcoar:affiliationName":[{"@value":"Center for Healthy Aging Universitätsklinikum Dresden Dresden Germany"},{"@value":"Department of Medicine III Universitätsklinikum Dresden Dresden Germany"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043772859266","@type":"Researcher","foaf:name":[{"@value":"Bart L Clarke"}],"jpcoar:affiliationName":[{"@value":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition Mayo Clinic Rochester MN USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043772859264","@type":"Researcher","foaf:name":[{"@value":"Douglas C Bauer"}],"jpcoar:affiliationName":[{"@value":"Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco CA USA"},{"@value":"Department of Medicine University of California, San Francisco San Francisco CA USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043772859267","@type":"Researcher","foaf:name":[{"@value":"Matthew T Drake"}],"jpcoar:affiliationName":[{"@value":"Robert and Arlene Kogod Center on Aging Mayo Clinic Rochester MN USA"},{"@value":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition Mayo Clinic Rochester MN USA"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"08840431"},{"@type":"EISSN","@value":"15234681"}],"prism:publicationName":[{"@value":"Journal of Bone and Mineral Research"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2020-05-14","prism:volume":"35","prism:number":"6","prism:startingPage":"1009","prism:endingPage":"1013"},"reviewed":"false","dc:rights":["https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model","http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjbmr.4049"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.4049"},{"@id":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jbmr.4049"},{"@id":"https://academic.oup.com/jbmr/article-pdf/35/6/1009/55453761/jbmr4049.pdf"}],"createdAt":"2020-05-14","modifiedAt":"2024-03-14","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050303564713710592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Role of sclerostin deletion in bisphosphonate-induced osteonecrosis of the jaw"}]},{"@id":"https://cir.nii.ac.jp/crid/1390571106617635840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of Postmenopausal Osteoporosis"},{"@language":"ja","@value":"閉経後骨粗鬆症"},{"@language":"ja-Kana","@value":"ヘイケイ ゴ コツソショウショウ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/jbmr.4049"},{"@type":"CROSSREF","@value":"10.4264/numa.80.4_181_references_DOI_VAT18ZJmYSiq3yrzrdFGtM5TmEo"},{"@type":"CROSSREF","@value":"10.1016/j.bone.2024.117200_references_DOI_VAT18ZJmYSiq3yrzrdFGtM5TmEo"}]}